SIGN UP
LOG IN
News
CPRX
15.53
+1.21%
0.19
Weekly Report: what happened at CPRX last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at CPRX last week (0401-0405)?
Weekly Report · 04/08 10:30
Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)
Catalyst Pharmaceuticals' stock has performed well, up approximately 20% since my previous "Buy" rating. Its stock price is no longer depressed, and its guidance for 2024 is unremarkable, leading to a downgrading to a "Hold" The company's acquisition of commercial rights to FYCOMPA has provided it with a second revenue stream. The deal's financial viability remains uncertain.
Seeking Alpha · 04/06 11:52
Top buy-rated stocks and sell-rated stocks within Health Care - Citi
Citi Research strategists have lowered the health care sector to underweight. The company has struggled with “uninspiring” growth in equipment and services. Pharmaceuticals, biotechnology and life sciences are the top sell-rated stocks within the sector. The top buy-rated stock is Arcus Biosciences.
Seeking Alpha · 04/04 15:12
Solid Biosciences gets FDA rare pediatric disease status for DMD therapy
Healthcare Solid Biosciences gets FDA rare pediatric disease status for DMD therapy. SGT-003 for the treatment of Duchenne muscular dystrophy. The company expects the first patient in a Phase 1/2 study for the therapy to be dosed in Q2.
Seeking Alpha · 04/01 14:17
Weekly Report: what happened at CPRX last week (0325-0329)?
Weekly Report · 04/01 10:29
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
7 analysts have expressed a variety of opinions on Catalyst Pharmaceuticals (NASDAQ:CPRX) over the past quarter. The company has an average price target of $29.29, with a 12-month average of $23.00. The biopharmaceutical company has a revenue growth rate of 81.98% over the last three months. Catalyst pharmaceuticals focuses on developing therapies for rare diseases.
Benzinga · 03/27 13:00
Analysts Are Bullish on Top Healthcare Stocks: Sutro Biopharma (STRO), Catalyst Pharma (CPRX)
2 analysts have maintained Buy ratings on Sutro Biopharma and Catalyst Pharma. Sutro has an analyst consensus of Strong Buy, with a price target of $11.17. Catalyst Pharma has a consensus of Buy with a $25.37 price target. Both companies are in the Healthcare sector.
TipRanks · 03/27 11:50
Catalyst Pharmaceuticals Price Target Maintained With a $29.00/Share by Oppenheimer
Dow Jones · 03/27 11:42
Oppenheimer Reiterates Outperform on Catalyst Pharmaceuticals, Maintains $29 Price Target
Benzinga · 03/27 11:32
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
Catalyst Pharmaceuticals, Inc. Will participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium taking place virtually on April 2-3, 2024. The company is a commercial-stage biopharmaceutical company focused on patients with rare and difficult-to-treat diseases.
Barchart · 03/27 07:03
Weekly Report: what happened at CPRX last week (0318-0322)?
Weekly Report · 03/25 10:32
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
NASDAQ · 03/20 09:14
Weekly Report: what happened at CPRX last week (0311-0315)?
Weekly Report · 03/18 10:30
Citi starts Catalyst at buy, cites rare disease drug portfolio
Healthcare Citi starts Catalyst at buy, cites rare disease drug portfolio. The investment bank said the company's flagship product Firdapse has the potential of hitting peak sales of more than $500M. Citi set its price target for the stock at $27.
Seeking Alpha · 03/14 19:09
Catalyst Pharmaceuticals Price Target Maintained With a $34.00/Share by Cantor Fitzgerald
Dow Jones · 03/14 14:29
Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $34 Price Target
Benzinga · 03/14 14:19
Catalyst Pharmaceuticals Initiated at Buy by Citigroup
Dow Jones · 03/14 12:12
Catalyst Pharmaceuticals Price Target Announced at $27.00/Share by Citigroup
Dow Jones · 03/14 12:12
Citigroup Initiates Coverage On Catalyst Pharmaceuticals with Buy Rating, Announces Price Target of $27
Benzinga · 03/14 12:02
More
Webull provides a variety of real-time CPRX stock news. You can receive the latest news about Catalyst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.